GenapSys secures $90 million in bid to upend sequencing

Following the raising of a $90 million Series C, privately held GenapSys will begin rolling out a line of low cost electronic-based genetic sequencing machines that it says could upend the research and clinical testing industries.

CEO Hesaam Esfandyarpour says the Redwood City, Calif.–based company’s Sequencer, a table-top device that carries a price tag that’s about 1/100th of existing systems, will make will make genetic sequencing available to the vast majority of research institutions that can’t currently afford larger systems that can cost up to $1 million.

Get the full story on our sister site MassDevice. 

---

Filed Under: Drug Discovery and Development, Genomics/Proteomics
Tagged With: GenapSys
 

---